CYP2C19 rs4986894: Understanding the *3 Loss-of-Function Variant
The rs4986894 variant, commonly known as the CYP2C19*3 allele, is a genetic change that reduces the activity of the CYP2C19 enzyme. This variant is clinically significant because it can impair the body's ability to activate certain medications, most notably the antiplatelet drug clopidogrel.
What each genotype means
Normal enzyme activity
This genotype represents the wild-type or functional status for this specific variant. Individuals with this result do not carry the loss-of-function *3 allele at this position, which is associated with reduced CYP2C19 enzyme activity. Please discuss your medication management and any concerns regarding drug metabolism with your clinician or pharmacist.
This is the most common genotype globally, though its frequency varies significantly by ancestry, being less common in populations with higher rates of the *3 loss-of-function allele.
Reduced enzyme activity
This genotype indicates you carry one copy of the *3 loss-of-function allele. Research suggests that carrying this variant can lead to reduced CYP2C19 enzyme activity, which may impact how your body processes certain medications like clopidogrel. You should discuss the clinical implications of this result and potential dosing adjustments with your healthcare provider or pharmacist.
This genotype is more frequently observed in East Asian populations compared to European or African populations, where it is relatively rare.
Significantly reduced enzyme activity
This genotype indicates you carry two copies of the *3 loss-of-function allele. This status is associated with a poor metabolizer phenotype, which may significantly impair the activation of prodrugs like clopidogrel. It is important to consult with your clinician or pharmacist to review your medication plan, as alternative therapies or dosage changes may be considered.
This genotype is rare in most global populations, though it is found at higher frequencies in East Asian populations compared to other ancestral groups.
What is the rs4986894 Variant?
The rs4986894 variant is a single nucleotide polymorphism (SNP) located within the CYP2C19 gene. In the scientific literature, this specific genetic change is widely recognized as the *3 allele. This variant acts as a loss-of-function mutation, meaning it disrupts the normal production or function of the CYP2C19 enzyme. Because enzymes are responsible for breaking down or activating substances in the body, a change in the genetic code can lead to significant differences in how individuals respond to various drugs. When a person carries this variant, the enzyme may be less efficient or completely inactive, which alters the metabolic pathway for medications that rely on this specific enzyme for processing.
The Role of the CYP2C19 Gene
The CYP2C19 gene provides the instructions for creating a member of the cytochrome P450 family of enzymes. These enzymes are primarily found in the liver and are essential for the metabolism of a wide range of compounds, including many commonly prescribed medications. For drugs like clopidogrel, which is used to prevent blood clots, the CYP2C19 enzyme is required to convert the inactive drug into its active, therapeutic form. If the enzyme is not functioning correctly due to a loss-of-function variant like rs4986894, the drug may not be converted effectively. This can result in lower levels of the active medication in the bloodstream, potentially reducing the drug's intended clinical effect.
Clinical Research and Evidence
Research into rs4986894 has established a strong association between this variant and reduced clopidogrel efficacy. Clinical studies have consistently shown that individuals carrying loss-of-function alleles, such as *2 and *3, may experience poor metabolism of clopidogrel. This is a critical area of pharmacogenomics, as the reduced antiplatelet effect can increase the risk of cardiovascular events in patients who require the medication for heart health. The evidence supporting this link is robust, leading to warnings in drug labeling regarding the potential for reduced effectiveness in poor metabolizers. It is important to note that while the association is strong, clinical outcomes can be influenced by many factors, including other genetic variants, drug interactions, and individual health history.
What You Can Do With This Information
Understanding your genetic profile regarding CYP2C19 can be a valuable tool for personalized medicine, but it should never be used to make independent medical decisions. If you have information about your genotype for rs4986894, the most important step is to share it with your healthcare provider or a clinical pharmacist. They are trained to interpret these results in the context of your overall health and current medication regimen. Never stop or change the dosage of a prescribed medication based on genetic test results without professional guidance. Your clinician can determine if alternative therapies or dosage adjustments are appropriate for your specific genetic profile, ensuring that your treatment plan is both safe and effective.
How common is this variant?
The frequency of the CYP2C19*3 allele varies significantly by ancestry, with higher prevalence observed in East Asian populations compared to European or African populations.
Frequently asked questions
What does it mean to be a 'poor metabolizer' for CYP2C19?
A poor metabolizer has genetic variants that significantly reduce or eliminate the activity of the CYP2C19 enzyme. This means the body cannot process certain drugs efficiently, which may lead to reduced drug effectiveness or unexpected side effects.
Does having the rs4986894 variant mean clopidogrel will not work for me?
Not necessarily, but it may mean the drug is less effective at preventing blood clots. You should discuss your genetic results with your doctor, who can evaluate if a different medication or a different dosage is better suited for you.
Are there other genes that affect clopidogrel?
Yes, clopidogrel metabolism is complex and can be influenced by other genes and environmental factors. Your healthcare provider can provide a comprehensive view of how your genetics might impact your response to various medications.
Should I get tested for CYP2C19 variants?
Genetic testing for pharmacogenomics is typically recommended by healthcare providers when it is clinically relevant to your treatment plan. You should consult with your doctor to see if such testing is appropriate for your specific medical situation.
Sources & further reading
Educational information only, last refreshed 9/15/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs4986894?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in CYP2C19
The CYP2C19*2 loss-of-function splicing defect results in impaired biotransformation of prodrugs including clopidogrel and altered clearance of proton pump inhibitors and select antidepressants.
Defines the CYP2C19*17 increased function allele, conferring rapid or ultrarapid metabolism for CPIC-actionable drugs including clopidogrel, PPIs, and SSRIs.
Variant in the CYP2C19 locus associated with altered metabolism of clopidogrel and proton-pump inhibitors.
Defines the CYP2C19*8 loss-of-function variant (c.358T>C, p.Trp120Arg) which results in no enzymatic activity and impaired metabolism of CYP2C19 substrates.
Defines the non-functional CYP2C19*3 null allele resulting from a premature stop codon, leading to poor metabolism of drugs such as clopidogrel, escitalopram, and proton pump inhibitors.
Defines the CYP2C19*4 allele caused by an ATG start codon alteration that abolishes translation, resulting in reduced or absent drug metabolism capacity.